Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease. This dermatologic condition was shown to resolve after successful anti-myeloma therapy. We report herein occurrence of pyoderma gangrenosum involving bilateral kne...
| Publicado en: | Journal of Oncology Pharmacy Practice Vol. 21; no. 6; pp. 471 - 474 |
|---|---|
| Autores principales: | , , |
| Formato: | case study pictorial tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
Dec2015
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110641362&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 110641362 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10781552 0JI jtl: Journal of Oncology Pharmacy Practice issn: 10781552 maglogo: Y pubinfo: dt: Dec2015 vid: 21 iid: 6 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 110641362 110641362 110641362 10.1177/1078155214541975 NLM24986794 110641362 ppf: 471 ppct: 3 formats: tig: atl: Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. aug: au: Dasanu, Constantin A. Bockorny, Bruno Alexandrescu, Doru T. affil: Department of Medicine, University of Connecticut, Farmington, CT, USA sug: subj: Multiple Myeloma Drug Therapy Thalidomide Administration and Dosage Thalidomide Adverse Effects Pyoderma Gangrenosum Chemically Induced Pyoderma Gangrenosum Diagnosis Aged, 80 and Over Male Skin Ulcer Etiology Prednisone Administration and Dosage Pyoderma Gangrenosum Therapy Occlusive Dressings Aged, 80 & over Male ab: Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease. This dermatologic condition was shown to resolve after successful anti-myeloma therapy. We report herein occurrence of pyoderma gangrenosum involving bilateral knees in a patient with multiple myeloma responding to lenalidomide therapy. Previous papers claimed usefulness of thalidomide and its newer derivatives for the therapy of this neutrophilic dermatosis. Occurrence of pyoderma gangrenosum in a myeloma patient responding to lenalidomide would argue against its effectiveness in treating this skin condition. Moreover, the clinical setting suggested that lenalidomide either induced or contributed to the occurrence of pyoderma gangrenosum in our patient. If our hypothesis is correct, we expect more reports of pyoderma gangrenosum with the use of this class of pharmaceuticals. pubtype: Academic Journal doctype: case study pictorial tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|